Effectiveness, safety, and pharmacokinetics of the infliximab biosimilar CT-P13 after non-medical switch from the infliximab originator in patients with inflammatory bowel disease.

Intest Res · 2026 · PMC13434528 · PMID 41338661

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

From this perspective, the results of this present study, which showed that NMS from IFX-O to IFX-BS in real-world clinical practice maintained a high remission rate and low frequency of adverse reactions in patients with IBD, are extremely significant.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.